NIPH Clinical Trials Search

JAPANESE
国立保健医療科学院
UMIN ID: UMIN000001386

Registered date:24/09/2008

Phase I/II study of complementary therapy using curcumin for gemcitabine-refractory pancreatic cancer patients

Basic Information

Recruitment status Complete: follow-up complete
Health condition(s) or Problem(s) studiedAdvanced pancreatic cancer patients who get refractory to gemcitabine-based chemotherapy
Date of first enrollment2008/09/01
Target sample size21
Countries of recruitmentJapan
Study typeInterventional
Intervention(s)Curcumin (8g/day) is orally added to gemcitabine-based chemotherapy until disease progression, unacceptable adverse events, patient withdrawal or death.

Outcome(s)

Primary OutcomePhase I; Safety Phase II; Feasibility of complementary therapy using curcumin
Secondary Outcome

Key inclusion & exclusion criteria

Age minimum20years-old
Age maximum80years-old
GenderMale and Female
Include criteria
Exclude criteria1. Patients with interstitial pneumonia or pulmonary fibrosis. 2. Patients with uncontrollable diabetes mellitus, liver disease, angina pectoris or a new onset of myocardial infarction within 3 months 3. Patients with severe infection. 4. Patients with history of severe drug allegy 5. Patients with other serious comorbid diseases 6. Patients with advanced cancer other than pancreatic cancer 7. Pregnant women or patients who wish pregnant 8. Patients with mental diseases 9. Patients who are judged inappropriate for the entry into the study by the investigater

Related Information

Contact

public contact
Name
Address Japan
Telephone 075-751-3397
E-mail
Affiliation Kyoto University Hospital Translational Research Center
scientific contact
Name Kanai Masashi
Address 54 Shogoin-Kawahara-cho 54, Sakyo-ku, Kyoto Japan
Telephone
E-mail
Affiliation Kyoto University Hospital Outpatient Oncology Unit